Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epcoritamab in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
NCT04542824Phase 2Active, not recruiting
- Sponsor
- Genmab
- Start
- Aug 2020
- Primary completion
- Sep 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epcoritamab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 3 more (5 arms), sponsored by Genmab. Primary endpoints: Treatment-emergent Adverse Events up to 5 years, Dose Limiting Toxicities at 28 days and 1 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
epcoritamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT04542824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542824.